阿托伐他汀联合曲美他嗪对冠心病患者Caspase-1和IL-18表达水平的影响

doi:10.3969/j.issn.1006-6233.2017.02.002

摘要
图/表
参考文献(6)
相关文章 (10)

全文: PDF (1325 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨阿托伐他汀联合曲美他嗪对患者进行治疗后,其体内Caspase-1和IL-18表达水平变化情况,为临床应用提供依据。方法: 将2013年7月至2015年7月间我院收治的100例冠心病患者随机分为观察组和对照组;对照组患者使用曲美他嗪治疗,观察组患者使用阿托伐他汀联合曲美他嗪进行治疗;在治疗结束后评估患者疗效,观察干预前及治疗结束后对患者血脂水平、血液流变学情况,并检测患者血清中Caspase-1和IL-18水平。结果: 观察组患者治疗有效率明显高于对照组,且差异存统计学意义(P<0.05);经治疗后,两组患者TC、TG、HDL-C及LDL-C水平均显著降低(P<0.05),且观察组水平显著低于对照组(P<0.05);两组患者红细胞比容、血浆粘度、低切变率下全血黏度及高切变率下全血黏度水平均显著降低(P<0.05),且观察组水平显著低于对照组(P<0.05);两组患者Caspase-1水平均显著降低(P<0.05),且观察组水平显著低于对照组(P<0.05);两组患者IL-18水平均显著降低(P<0.05),且观察组水平显著低于对照组(P<0.05)。结论: 采用曲美他嗪与阿托伐他汀对冠心病患者干预后,可有效改善患者血脂及血液流变学情况,降低血清中Caspase-1及下游IL-18水平,具有较高的临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	袁小蓉
	徐苹
	杨博

关键词 ：阿托伐他汀, 曲美他嗪, 冠心病, Caspase-1, IL-18

Abstract：Objective: To investigate the effects of atorvastatin combined with trimetazidine for the treatment of patients after the in vivo Caspase-1 and IL-18 expression changes. Methods: 100 cases of patients with coronary heart disease (CHD) admitted in our hospital from July 2013 to July 2015 were randomly divided into observation group and control group; the control group was treated with trimetazidine treatment, observation group were treated with atorvastatin combined with trimetazidine treatment sibutramine; patients after the treatment, assessment, intervention at the end of the observation before and after treatment in patients with blood rheology blood lipid levels, learning condition, and the levels of Caspase-1 and IL-18 in serum. Results: The effective rate of the observation group was significantly higher than the control group, and the difference has statistical significance (P<0.05); After treatment, The TC, TG, HDL-C and LDL-C levels of Patients were significantly decreased (P<0.05), and the observation group was significantly lower than that of control group (P<0.05); red blood cell hematocrit and plasma viscosity the whole blood viscosity and low shear rate and high shear rate of whole blood viscosity patients was significantly reduced (P<0.05), and the observation group was significantly lower than that of control group (P<0.05);The Caspase-1 levels of patients two groups were significantly decreased (P<0.05), and the observation group was significantly lower than that of control group (P<0.05); IL-18 in two groups significantly decreased (P<0.05), and the observation group was significantly lower than that of control group (P<0.05). Conclusion: The trimetazidine and atorvastatin on the prognosis of patients with CHD can improve the blood lipid and blood rheology in patients with learning condition, reduce the levels of Caspase-1 and lower the level of IL-18, it has high value in clinical application.

Key words： Atorvastatin Trimetazidine Coronary heart disease Caspase-1 IL-18

基金资助:四川省科技厅资助项目,(编号:2015026352)

引用本文:

袁小蓉, 徐苹, 杨博. 阿托伐他汀联合曲美他嗪对冠心病患者Caspase-1和IL-18表达水平的影响[J]. 河北医学, 2017, 23(2): 180-183.
YUAN Xiaorong, XU Ping, YANG Bo. Atorvastatin Combined with Trimetazidine on the Expression Level of Caspase-1 and IL-18 of patients with CHD. HeBei Med, 2017, 23(2): 180-183.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2017.02.002 或 http://www.hbyxzzs.cn/CN/Y2017/V23/I2/180